Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 3/2016

Open Access 01-09-2016 | Clinical Trials (S Hurvitz, Section Editor)

Reducing the Risk of Breast Cancer Recurrence: an Evaluation of the Effects and Mechanisms of Diet and Exercise

Authors: Christina M. Dieli-Conwright, Kyuwan Lee, Jacqueline L. Kiwata

Published in: Current Breast Cancer Reports | Issue 3/2016

Login to get access

Abstract

With recent medical advances in diagnosis and treatment, the increasing numbers of long-term survivors of breast cancer is considerable and has resulted in the expansion of scientific research to include examination of lifestyle modifications as means of prevention of recurrence, new breast cancer events, and mortality. The objective of this report is to review randomized controlled trials (RCTs) including diet and/or exercise interventions on breast cancer recurrence in women with a history of breast cancer as well as pertinent recent epidemiologic evidence. Implicated biologic mechanisms are discussed to elucidate the impact of diet and exercise on disease recurrence.
Literature
1.
2.
Demark-Wahnefried W, Campbell KL, Hayes SC. Weight management and its role in breast cancer rehabilitation. Cancer. 2012;118(8 Suppl):2277–87.CrossRefPubMed
3.
Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer. 2011;105 Suppl 1:S52–73.CrossRefPubMedPubMedCentral
4.
Marmot M, Atinmo T, Byers T, Chen J, Hirohata T, Jackson A, James W, Kolonel L, Kumanyika S, Leitzmann C: Food, nutrition, physical activity, and the prevention of cancer: a global perspective. 2007
5.
Patterson RE, Cadmus LA, Emond JA, Pierce JP. Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas. 2010;66(1):5–15.CrossRefPubMed
6.
Rock CL, Doyle C, Demark‐Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62(4):242–74.CrossRef
7.
Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst. 2006;98(24):1767–76.CrossRefPubMed
8.
Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial. Jama. 2007;298(3):289–98.CrossRefPubMedPubMedCentral
9.
Chlebowski R, Blackburn G, Hoy M, Thomson C, Giuliano A, McAndrew P, Hudis C, Butler J, Shapiro A, Elashoff R: Survival analyses from the Women’s Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome. In: ASCO Annual Meeting Proceedings: 2008; 2008: 522
10.
Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer. 2012;19(5):F27–45.CrossRefPubMed
11.
Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res. 2013;19(22):6074–83.CrossRefPubMedPubMedCentral
12.
13.•
Belardi V, Gallagher EJ, Novosyadlyy R, LeRoith D. Insulin and IGFs in obesity-related breast cancer. J Mammary Gland Biol Neoplasia. 2013;18(3-4):277–89. This review discusses the role of the insulin-family hormones, factors and receptors in obesity-associated tumor progression and metastases in breast cancer. CrossRefPubMed
14.
Werner H. Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene. 2012;31(22):2703–14.CrossRefPubMed
15.
Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008;68(24):10238–46.CrossRefPubMed
16.
17.
Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004;114(4):569–81.CrossRefPubMedPubMedCentral
18.
Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila). 2011;4(7):1021–9.CrossRef
19.
Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009;28(33):2940–7.CrossRefPubMed
20.
Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer discovery. 2012;2(4):356–65.CrossRefPubMedPubMedCentral
21.
Zhou J, Suzuki T, Kovacic A, Saito R, Miki Y, Ishida T, et al. Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Res. 2005;65(2):657–63.PubMed
22.
Vadodkar AS, Suman S, Lakshmanaswamy R, Damodaran C. Chemoprevention of breast cancer by dietary compounds. Anti Cancer Agents Med Chem. 2012;12(10):1185–202.CrossRef
23.
Gold EB, Pierce JP, Natarajan L, Stefanick ML, Laughlin GA, Caan BJ, et al. Dietary pattern influences breast cancer prognosis in women without hot flashes: the women’s healthy eating and living trial. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(3):352–9.CrossRef
24.
Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson CA, Natarajan L, et al. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res Am Soc Prev Oncol. 2008;17(3):614–20.CrossRef
25.
Thomson CA, Rock CL, Thompson PA, Caan BJ, Cussler E, Flatt SW, et al. Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women’s Healthy Eating and Living Study. Breast Cancer Res Treat. 2011;125(2):519–27.CrossRefPubMed
26.
Nahum A, Zeller L, Danilenko M, Prall OW, Watts CK, Sutherland RL, et al. Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. Eur J Nutr. 2006;45(5):275–82.CrossRefPubMed
27.
Hirsch K, Atzmon A, Danilenko M, Levy J, Sharoni Y. Lycopene and other carotenoids inhibit estrogenic activity of 17beta-estradiol and genistein in cancer cells. Breast Cancer Res Treat. 2007;104(2):221–30.CrossRefPubMed
28.
Rock CL, Flatt SW, Thomson CA, Stefanick ML, Newman VA, Jones LA, et al. Effects of a high-fiber, low-fat diet intervention on serum concentrations of reproductive steroid hormones in women with a history of breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(12):2379–87.CrossRef
29.
Kendall ME, Cohen LA. Effect of dietary fiber on mammary tumorigenesis, estrogen metabolism, and lipid excretion in female rats. In Vivo. 1992;6(3):239–46.PubMed
30.
Caan BJ, Natarajan L, Parker B, Gold EB, Thomson C, Newman V, et al. Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res Am Soc Prev Oncol. 2011;20(5):854–8.CrossRef
31.
Fink BN, Steck SE, Wolff MS, Britton JA, Kabat GC, Gaudet MM, et al. Dietary flavonoid intake and breast cancer survival among women on Long Island. Cancer Epidemiol biomarkers Prev Publ Am Assoc Cancer Res Am Soc Prev Oncol. 2007;16(11):2285–92.CrossRef
32.
Guha N, Kwan ML, Quesenberry Jr CP, Weltzien EK, Castillo AL, Caan BJ. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat. 2009;118(2):395–405.CrossRefPubMedPubMedCentral
33.
Nechuta SJ, Caan BJ, Chen WY, Lu W, Chen Z, Kwan ML, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. 2012;96(1):123–32.CrossRefPubMedPubMedCentral
34.
35.
Taylor CK, Levy RM, Elliott JC, Burnett BP. The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr Rev. 2009;67(7):398–415.CrossRefPubMed
36.
Lamartiniere CA, Moore JB, Brown NM, Thompson R, Hardin MJ, Barnes S. Genistein suppresses mammary cancer in rats. Carcinogenesis. 1995;16(11):2833–40.CrossRefPubMed
37.
Vantyghem SA, Wilson SM, Postenka CO, Al-Katib W, Tuck AB, Chambers AF. Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. Cancer Res. 2005;65(8):3396–403.PubMed
38.
Jacobs ET, Thomson CA, Flatt SW, Al-Delaimy WK, Hibler EA, Jones LA, et al. Vitamin D and breast cancer recurrence in the Women’s Healthy Eating and Living (WHEL) Study. Am J Clin Nutr. 2011;93(1):108–17.CrossRefPubMed
39.
Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, et al. Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657). Cancer Med. 2014;3(3):693–701.CrossRefPubMedPubMedCentral
40.•
Lohmann AE, Chapman JA, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, et al. Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Res Treat. 2015;150(3):605–11. This observational study nested in a phase III adjuvant trial examined the association between vitamin D levels and measures of recurrence and survival in breast cancer survivors. They reported no association between vitamin D level and any outcome. CrossRefPubMed
41.
Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(29):3869–76.CrossRef
42.
Krishnan AV, Swami S, Feldman D. Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol. 2010;121(1-2):343–8.CrossRefPubMed
43.
Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(23):3757–63.CrossRef
44.
Vrieling A, Hein R, Abbas S, Schneeweiss A, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast cancer research : BCR. 2011;13(4):R74.CrossRefPubMedPubMedCentral
45.
Artinian NT, Fletcher GF, Mozaffarian D, Kris-Etherton P, Van Horn L, Lichtenstein AH, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults a scientific statement from the American Heart Association. Circulation. 2010;122(4):406–41.CrossRefPubMed
46.
Arnold M, Leitzmann M, Freisling H, Bray F, Romieu I, Renehan A, et al. Obesity and cancer: an update of the global impact. Cancer Epidemiol. 2016;41:8–15.CrossRefPubMed
47.
Noguchi JL, Liss MA, Parsons JK: Obesity, Physical Activity and Bladder Cancer. Curr Urol Rep 2015, 16(10).
48.
Hartman SJ, Marinac C, Natarajan L, Patterson R. Obesity, physical activity, and sleep may impact cognitive functioning in breast cancer survivors. Ann Behav Med. 2014;47:S237.
49.
Lee JK, So KA, Piyathilake CJ, Kim MK: Mild Obesity, Physical Activity, Calorie Intake, and the Risks of Cervical Intraepithelial Neoplasia and Cervical Cancer. PloS one 2013, 8(6).
50.
Martin E, Bulsara C, Battaglini C, Hands B, Naumann FL. Breast and prostate cancer survivor responses to group exercise and supportive group psychotherapy. J Psychosoc Oncol. 2015;33(6):620–34.CrossRefPubMed
51.
Falzon C, Radel R, Cantor A, d’Arripe-Longueville F. Understanding narrative effects in physical activity promotion: the influence of breast cancer survivor testimony on exercise beliefs, self-efficacy, and intention in breast cancer patients. Support Care Cancer. 2015;23(3):761–8.CrossRefPubMed
52.
Klika RJ, Callahan KE, Golik KS. Exercise capacity of a breast cancer survivor: a case study. Med Sci Sports Exerc. 2008;40(10):1711–6.CrossRefPubMed
53.
Loprinzi PD, Cardinal BJ, Winters-Stone K, Smit E, Loprinzi CL. Physical activity and the risk of breast cancer recurrence: a literature review. Oncol Nurs Forum. 2012;39(3):269–74.CrossRefPubMed
54.•
Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity, risk of death and recurrence in breast cancer survivors: a systematic review and meta-analysis of epidemiological studies. Acta Oncol. 2015;54(5):635–54. This systematic review and meta-analysis is the most recent and thorough evaluation of physical activity and its effects on breast cancer outcomes, including 22 prospective studies. CrossRefPubMed
55.
Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. Jama-J Am Med Assoc. 2005;293(20):2479–86.CrossRef
56.••
Courneya KS, Segal RJ, McKenzie DC, Dong H, Gelmon K, Friedenreich CM, et al. Effects of exercise during adjuvant chemotherapy on breast cancer outcomes. Med Sci Sports Exerc. 2014;46(9):1744–51. This multicenter RCT is the first trial to examine the effects of exercise on breast cancer outcomes and further demonstrated that exercise may improve these outcomes. CrossRefPubMed
57.
Dieli-Conwright CM, Mortimer JE, Schroeder ET, Courneya K, Demark-Wahnefried W, Buchanan TA, et al. Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods. BMC Cancer. 2014;14:238.CrossRefPubMedPubMedCentral
58.
59.
Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD, Frohlich JJ. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care. 2003;26(11):2977–82.CrossRefPubMed
60.
Rock CL, Pande C, Flatt SW, Ying C, Pakiz B, Parker BA, et al. Favorable changes in serum estrogens and other biologic factors after weight loss in breast cancer survivors who are overweight or obese. Clin Breast Cancer. 2013;13(3):188–95.CrossRefPubMedPubMedCentral
61.
Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors a randomized controlled trial. Cancer Epidemiol Biomark. 2003;12(8):721–7.
62.
Irwin ML, Varma K, Alvarez-Reeves M, Cadmus L, Wiley A, Chung GG, et al. Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer Epidemiol Biomark. 2009;18(1):306–13.CrossRef
63.
Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, et al. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol. 2008;26(6):907–12.CrossRefPubMed
64.
Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomark. 2005;14(7):1672–80.CrossRef
65.
Macciò A, Madeddu C, Gramignano G, Mulas C, Floris C, Massa D, et al. Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med. 2010;88(7):677–86.CrossRefPubMed
66.••
Schmidt S, Monk J, Robinson L, Mourtzakis M. The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: potential effects of exercise. Obes Rev. 2015;16(6):473–87. This recent review discusses plausible mechanisms underlying the relationship between leptin and obesity, and how energy expenditure through exercise can mediate their interaction. CrossRefPubMedPubMedCentral
67.
Rogers LQ, Fogleman A, Trammell R, Hopkins-Price P, Vicari S, Rao K, Edson B, Verhulst S, Courneya KS, Hoelzer K: Effects of a physical activity behavior change intervention on inflammation and related health outcomes in breast cancer survivors: pilot randomized trial. Integrative cancer therapies 2012:1534735412449687
68.
Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409–26.CrossRefPubMed
69.
Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, et al. American cancer society guidelines on nutrition and physical activity for cancer prevention reducing the risk of cancer with healthy food choices and physical activity. Ca-Cancer J Clin. 2012;62(1):30–67.CrossRefPubMed
70.
Committee PAGA. Physical activity guidelines advisory committee report. Washington, DC: US Department of Health and Human Services; 2008.
71.••
Rock CL, Flatt SW, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, et al. Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: a behavioral weight loss intervention in overweight or obese breast cancer survivors. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(28):3169–76. The ENERGY RCT is the largest weight loss intervention trial among breast cancer survivors and demonstrated that a behavioral weight loss intervention can be effective at reducing body weight and circulating levels of estrogens and cytokines implicated in recurrence. CrossRef
72.
Scott E, Daley AJ, Doll H, Woodroofe N, Coleman RE, Mutrie N, et al. Effects of an exercise and hypocaloric healthy eating program on biomarkers associated with long-term prognosis after early-stage breast cancer: a randomized controlled trial. Cancer Causes Control : CCC. 2013;24(1):181–91.CrossRefPubMed
73.
Villarini A, Pasanisi P, Traina A, Mano MP, Bonanni B, Panico S, et al. Lifestyle and breast cancer recurrences: the DIANA-5 trial. Tumori. 2012;98(1):1–18.PubMed
74.
Pierce JP, Stefanick ML, Flatt SW, Natarajan L, Sternfeld B, Madlensky L, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clinical Oncol Off J Am Soc Clin Oncol. 2007;25(17):2345–51.CrossRef
75.
Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol Off J Am Socc Clin Oncol. 2002;20(4):1128–43.CrossRef
76.
Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat. 2008;111(2):329–42.CrossRefPubMed
Metadata
Title
Reducing the Risk of Breast Cancer Recurrence: an Evaluation of the Effects and Mechanisms of Diet and Exercise
Authors
Christina M. Dieli-Conwright
Kyuwan Lee
Jacqueline L. Kiwata
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 3/2016
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-016-0218-3

Other articles of this Issue 3/2016

Current Breast Cancer Reports 3/2016 Go to the issue

Risk and Prevention (TB Bevers, Section Editor)

Physician and Patient Barriers to Breast Cancer Preventive Therapy

Risk and Prevention (TB Bevers, Section Editor)

Update on Breast Cancer Risk Reduction Therapy

Risk and Prevention (TB Bevers Section Editor)

Current Approach to Breast Cancer Risk Reduction for Women with Hereditary Predispositions to Breast Cancer

Invited Commentary

Aromatase Inhibitor-Associated Arthralgia: How Big Is the Problem and What Can Be Done?

Clinical Trials (S Hurvitz, Section Editor)

Screening for Cognitive Impairment Associated with Chemotherapy for Breast Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits